Featured Research

from universities, journals, and other organizations

Finasteride May Help Prevent Development Of Prostate Cancer, Study Shows

Date:
May 20, 2008
Source:
American Association for Cancer Research
Summary:
A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.

A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.

Related Articles


A pathologic analysis of that same study sheds light on the significance of the cancers found in that study. Additionally, this study highlights the role of prostate specific antigen (PSA) scores in treatment decision-making. Researchers found that even those men who have a low PSA screening value can have cancer that is difficult to cure.

The two studies will be published online in advanced of the June 2008 issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

The original study, the Prostate Cancer Prevention Trial (PCPT), had randomized 18,822 men to receive either a placebo or an agent known as finasteride, currently approved to control prostate growth, for seven years. Results showed that while finasteride reduced prostate cancer risk by 25 percent, it appeared to increase development of more aggressive prostate cancer in some men. Because of this finding and concerns that tumors detected had low PSA values and might be of little risk to patients, since the study's original publication in 2003, few doctors have recommended finasteride for prostate cancer prevention.

From a new analysis of PCPT data using advanced statistical modeling techniques and a complete assessment of prostate tissue biopsies, they concluded that these concerns are now resolved: finasteride actually reduced the risk of developing prostate cancer more than researchers had originally thought, did not increase development of more aggressive cancers, and the majority of tumors prevented were those that could spread and cause death.

These new findings suggest that men should take an "individualized" approach to prostate cancer prevention, said Ian M. Thompson, M.D., Chair of the Department of Urology at the University of Texas Health Sciences Center at San Antonio, who is senior author on both studies, and was also lead author for the Southwest Oncology Group (SWOG) on the original PCPT results paper, which was published in July 2003.

"Because we now know that men with even low PSAs can develop prostate tumors, if a man is worried about his risk, regardless of PSA score, he can take an agent that is now proven to be effective in lowering that risk," Thompson said.

Researchers looked at whether finasteride actually increased aggressive cancers in some men, and by studying biopsies and prostate gland tissue that had been removed, concluding that it did not. "Finasteride actually shrank the prostate gland, so it appeared in initial studies that more cancer was being found in biopsies of men who took the drug," said Mary Redman, Ph.D., a biostatistician at the Fred Hutchinson Cancer Research Center.

"What that means is that the cancer took up more prostate tissue in men who were treated, and that is why it was easier to find in a biopsy. Cancer was probably missed more often in biopsies of men on a placebo drug because the prostate gland itself was larger," Redman said.

Redman found that in addition to a 25 to 30 percent reduction in prostate cancer development overall in men taking finasteride, there was no evidence that the drug increased the rate of aggressive tumors and likey decreased their rate by 27 percent.

"We think men should not be concerned about finasteride increasing their risk of these aggressive tumors" she said.

The second study examined whether the cancers detected in the men in the trial who had a low PSA level had clinically significant disease. With about 75 percent of the tumors detected on the study were classified as those which could potentially take a man's life, researchers concluded that there is no clear-cut PSA threshold that can be considered normal.

All patients in PCPT were to have a biopsy of their prostate gland at some point during the seven-year trial, so investigators evaluated characteristics of the biopsy in relation to each man's PSA score. Current practice is to consider a PSA score of below four as normal and above four as abnormal.

What they found, according to lead author Scott Lucia, M.D., a pathologist at the University of Colorado, Denver, was that while a large majority of the participants diagnosed with prostate cancer had a PSA that was considered normal, 72 percent of all tumors diagnosed from biopsies in both treated and untreated men were considered significant. In short, the finding of significant disease couldn't be predicted by the PSA score, he said. Most patients in the study who had a PSA score of four or less and then had prostate cancer diagnosed by a routine biopsy were found to have significant prostate cancer, while some men who had a high PSA were found to have insignificant cancer.

That doesn't mean that the researchers support reducing the level by which PSA scoring should trigger therapeutic intervention, Lucia said. "Over 90 percent of men in the country diagnosed with prostate cancer opt for treatment, yet we also found that even at higher PSA levels, men are being treated for tumors that would not have threatened their health," he said. "This is the dilemma of PSA screening. While lower cut-off levels, those below four, increase risk of detection of insignificant disease, cure is more likely; conversely, more significant disease is detected with higher levels but at a greater risk of incurable disease."

It does mean that men need to speak with their physicians about their PSA, when they should be biopsied, and about potential use of finasteride, which can reduce their risk, so that they will make a decision that is right for them, researchers say. For example, Lucia says, a man whose family members have been diagnosed with the disease may decide to have a biopsy even though his PSA is below four. If cancer is found then may opt to undergo treatment; if cancer is not found, he may choose to use finasteride to prevent the cancer from developing. Another man may decide to put off a biopsy, regardless of PSA score, if he is worried about side effects of treatment.

"These are not easy decisions, especially when we know now that we cannot rely on what the PSA looks like it is telling us," Lucia said.

Emphasizing the importance of prevention, "if given the option of having my prostate cancer found early, getting it treated and then getting over the side effects of treatment or never getting cancer in the first place, I'd choose prevention any day," said Thompson.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Finasteride May Help Prevent Development Of Prostate Cancer, Study Shows." ScienceDaily. ScienceDaily, 20 May 2008. <www.sciencedaily.com/releases/2008/05/080518152633.htm>.
American Association for Cancer Research. (2008, May 20). Finasteride May Help Prevent Development Of Prostate Cancer, Study Shows. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2008/05/080518152633.htm
American Association for Cancer Research. "Finasteride May Help Prevent Development Of Prostate Cancer, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2008/05/080518152633.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins